An analysis of HER2-mutant subgroups indicated that patients with the HER2 YVMA mutation were significantly more likely to develop brain metastases on treatment than patients in the KRAS cohort but not patients in the EGFR cohort or patients with HER2 non-YVMA mutations (Table 2 and Supporting Fig. 1A)..